Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.57 |
| ▸ | STK4 | Q13043 | 6/20 | 0.57 |
| ▸ | STK3 | Q13188 | 6/20 | 0.57 |
| ▸ | ITK | Q08881 | 7/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | MERTK | Q12866 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301607 | 0.86 | LRRK2 (0.59) | LRRK2STK4STK3ITKMET | |
| SCHEMBL31301757 | 0.85 | LRRK2 (0.58) | LRRK2STK4STK3ITKMET | |
| SCHEMBL31301605 | 0.85 | LRRK2 (0.55) | LRRK2STK4STK3ITKMET | |
| SCHEMBL31301784 | 0.84 | LRRK2 (0.61) | LRRK2STK4STK3ITKMET | |
| SCHEMBL31301715 | 0.83 | LRRK2 (0.55) | LRRK2STK4STK3ITKMET | |
| SCHEMBL31301696 | 0.76 | STK3 (0.59) | LRRK2STK4STK3METAXL | |
| SCHEMBL31301567 | 0.75 | STK3 (0.58) | LRRK2STK4STK3ITKMET | |
| SCHEMBL31301644 | 0.74 | STK3 (0.55) | LRRK2STK4STK3ITKMET | |
| SCHEMBL15401357 | 0.73 | LRRK2 (1.00) | LRRK2STK4STK3 | |
| SCHEMBL31301711 | 0.71 | LRRK2 (0.59) | LRRK2STK4STK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | STK3, STK4, STK36 | LRRK2 210/4885STK4 2/4885STK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.